GlassScriptPhysician profile
Andrew A Johnstone
NPI 1508831140
$3,791.55
in general payments reported to CMS, 2019-2025
41 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $838 · 2021: $909 · 2022: $268 · 2023: $309 · 2024: $320 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.92 | 2019-2025 | |
| Novo Nordisk INC | $550.70 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $359.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.42 | 2019-2022 | |
| Lilly USA, LLC | $172.72 | 2019-2023 | Mounjaro |
| Amgen INC. | $160.00 | 2019-2023 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $155.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.61 | 2019-2022 | |
| Antares Pharma, INC. | $137.51 | 2019-2024 | Xyosted |
| Amarin Pharma, INC. | $127.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $94.15 | 2019-2022 | |
| Esperion Therapeutics, INC. | $90.67 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $82.90 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.05 | 2024-2025 | Caplyta |
| Abbott Laboratories | $59.66 | 2023-2024 | Freestyle Libre 3 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Johnstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.